The ACC 2026 Updates on Redefining Hypertension Management: Translating Evidence on End Organ Protection

Following the conclusion of American College of Cardiology (ACC) 2026 conference held between March 28–30, 2026, New Orleans, LA, United States), a pan-India expert meeting was conducted to discuss key hypertension updates, featuring insights from Prof. Keith C. Ferdinand, Professor of Medicine, Gerald S. Berenson Endowed Chair in Preventative Cardiology at Tulane University School of Medicine, Louisiana, USA and Dr. Jamshed J. Dalal, Senior Interventional Cardiologist and Director at Kokilaben Dhirubhai Ambani Hospital, Mumbai, India highlighting evolving strategies in hypertension management.

ACC/AHA Hypertension Guideline Updates & Evidence: Risk-Based BP Targets and Intensive BP Control

The American College of Cardiology/American Heart Association (ACC/AHA) 2025 hypertension guidelines highlight a continuous relationship between blood pressure and cardiovascular risk, with pooled analyses (>340,000 individuals) showing that BP reduction lowers cardiovascular events regardless of baseline levels, supporting a “lower is better” approach¹. The STEP trial (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients) demonstrated that intensive systolic BP control in adults ≥60 years reduced stroke and all-cause mortality². Evidence from ESPRIT (Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs) and BP-ROAD trials (Blood Pressure Control Target in Diabetes) further supported lower BP targets (<130/80 mmHg), particularly in high-risk populations including diabetes³. The China Rural Hypertension Control Study showed that aggressive BP lowering also reduced cognitive decline and dementia risk⁴. Lifestyle modification remains foundational, including weight reduction, DASH diet, sodium restriction, physical activity, and stress control. Patients with diabetes and CKD require tighter BP targets, with ARBs or ACE inhibitors preferred to reduce cardiovascular and renal risk, with early consideration of single-pill combination therapy⁵.

ACC 2026 Updates: Key Research in Hypertension

• Global Burden of Hypertensive Heart Disease (HHD)⁶: A global analysis across nearly ~200 countries assessed prevalence, mortality, and disability-adjusted life years associated with hypertensive heart disease. The study showed an increasing prevalence of HHD and related mortality worldwide. Older individuals were most affected, with the highest prevalence in the 70-74 year age group and highest mortality in those aged 80–84 years. Women demonstrated accelerated risk post-menopause. These findings highlight and reflect the growing burden of hypertension globally.
• Hypertension and Atrial Fibrillation Mortality (CDC–NHANES Analysis)⁷: An analysis using CDC national data and NHANES datasets evaluated hypertension-related atrial fibrillation mortality between 2017 and 2022. Atrial fibrillation mortality increased across populations, with uncontrolled hypertension contributing to nearly two-thirds of deaths. Mortality risk was three- to four-fold higher in patients with diabetes. Higher mortality was also observed in women, rural populations, and socioeconomically vulnerable groups. These findings emphasize the importance of BP control in reducing atrial fibrillation-related mortality.
• Underutilization of Single-Pill Combination Therapy⁸: A retrospective real-world analysis presented at ACC 2026 evaluated the use of single-pill combination therapy. Despite strong recommendations from ACC/AHA, ESC, and ESH guidelines supporting early combination therapy, only 13.8% of patients were treated with fixed-dose combinations. Usage declined over time and was lower in populations with high social vulnerability. These findings highlight a major gap between guideline recommendations and real-world clinical practice.
• Telmisartan in Metabolic Dysfunction–Associated Steatotic Liver Disease(MASLD)⁹: A retrospective cohort study evaluated cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease treated with telmisartan compared with other ARBs. Over ~5 years, telmisartan was associated with 45% lower risk of major cardiovascular events, including 36% lower risk of ischemic heart disease(IHD), 44% lower risk of arrhythmia, 43% lower risk of stroke, and 41% lower risk of heart failure.

• Blood Pressure Variability and Clinical Outcomes¹⁰: An updated meta-analysis evaluated long-term blood pressure variability across nine cohorts, including approximately 3.2 million individuals. Increased BP variability was associated with higher all-cause mortality, stroke risk, and cardiovascular mortality. These findings suggest that stable BP control may be as important as absolute BP reduction and that BP variability may become an important risk stratification marker in hypertensive patients. These findings also suggest the importance of rigorous out-of-office blood pressure monitoring in the real-world.
• THRIVE Lifestyle Intervention Study¹¹: The THRIVE program evaluated a structured lifestyle intervention using DASH diet counseling and digital support. Participants demonstrated approximately 6.8 mmHg reduction in systolic BP at 24 weeks, with improved adherence and high patient satisfaction. These findings highlight the benefit of structured lifestyle and digital interventions in hypertension management.
• KARDINAL Study¹²: The KARDINAL trial evaluated Tonlamarsen, an RNA-targeted therapy, more specifically classified as an antisense oligonucleotide (ASO) therapy, in patients with uncontrolled hypertension. The study demonstrated a significant reduction in angiotensinogen levels and meaningful BP lowering compared with placebo, highlighting emerging therapeutic approaches. However, more robust and diverse studies are needed in the future with this group of agents.
• Low-Dose Combination Therapy Meta-analysis¹³: A systematic review and meta-analysis of 12 RCTs (n=6532; follow-up 4–12 weeks) showed that low-dose multi-drug therapy significantly improved BP control (RR 2.17 vs placebo; RR 1.37 vs active) and reduced SBP (−14.97 mmHg vs placebo; −6.18 mmHg vs active). The benefit was consistent across subgroups with comparable safety, supporting early use of low-dose combination therapy over monotherapy in hypertension.
• Groceries for black residents of BOSTON to stop HTN in adults with treated HTN (GOFRESH-RX)¹⁴: A lifestyle intervention study providing DASH-style groceries with dietitian support showed greater reductions in systolic and diastolic BP compared with a self-directed diet. Improvements were also observed in sodium-potassium balance and lipid parameters, including LDL-C levels.

Indian Expert Perspective on ACC 2026 Hypertension Updates

• Indian Perspective: Hypertension Burden and Management: Indian data highlight a high prevalence of hypertension with significant gaps in diagnosis, treatment, and control. Stage 2 hypertension represents a high cardiovascular risk state requiring early intervention¹⁵. Early initiation of combination therapy enables faster BP reduction and improves long-term outcomes. Long-acting agents and home BP monitoring were emphasized to achieve stable 24-hour BP control and improve adherence¹⁶.
• India Ahead of the World in Access to Wide Single Pill Combination(SPC) Options for Hypertension¹⁵: Compared to western countries, India has long had access to a broader range of single-pill combination antihypertensive therapies. While evidence and guideline emphasis continue to evolve, these SPCs should be used more effectively in appropriate patients to improve BP control and real-world outcomes.
• The telmisartan–amlodipine combination provides complementary mechanisms through RAAS blockade and calcium channel inhibition, both long-acting agents, enabling effective reduction in both systolic and diastolic blood pressure with sustained 24-hour control¹⁷.
• Early use of telmisartan plus amlodipine supports faster achievement of BP targets hypertension, while using moderate doses helps reduce dose-related adverse effects and improves tolerability¹⁷.
• Evidence from the TACT India study (~6,500 patients) demonstrated significant BP reduction, with nearly 70% of patients achieving target BP, supporting the role of telmisartan–amlodipine as an early combination therapy¹⁸.
• The START-RENAL study comparing telmisartan–amlodipine with telmisartan–cilnidipine demonstrated effective BP reduction, supporting telmisartan–amlodipine as a suitable dual therapy option in patients requiring early combination treatment, including those with renal risk¹⁹.

References:

1) Rahimi K, Bidel Z, Nazarzadeh M, et al. The Lancet. 2021;397(10285):1625-1636.

2) Zhang S, et al. STEP Study Group. Strategy of blood pressure intervention in the elderly hypertensive patients (STEP): Rational, design, and baseline characteristics for the main trial. Contemp Clin Trials. 2020 Feb;89:105913. doi: 10.1016/j.cct.2019.105913. Epub 2019 Dec 12. PMID: 31838255.

3) Kreutz R, Brunström M. Lowering of systolic blood pressure with ESPRIT along the BPROAD: the lower the better? Clin Hypertens. 2025 May 1;31:e20. doi: 10.5646/ch.2025.31.e20. PMID: 40336509; PMCID: PMC12055493.

4) China Rural Hypertension Control Project. (2018). China rural hypertension control project (ClinicalTrials.gov Identifier: NCT03527719). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03527719

5) Jones. D, Ferdinand. K, Taler. S, et al JACC VOL. 86, NO. 18, 2025 NOVEMBER 4, 2025:1567 – 1678

6) Thota, A, Gujjari, S, Gera, A. et al. 26-A-20368-ACC HYPERTENSIVE HEART DISEASE AS A GLOBAL WARNING SIGNAL: RISING PREVALENCE, PERSISTENT DEATHS, AND NEW FRONTIERS FOR ACTION. JACC. 2026 Apr, 87 (13_Supplement) A334. https://doi.org/10.1016/j.jacc.2026.02.825

7) Shakeel, R, Ahmad Chaudhry, S, NAWAZ, H. et al. 26-A-20798-ACC HYPERTENSION-DRIVEN ATRIAL FIBRILLATION MORTALITY: A CDC WONDER-NHANES ANALYSIS OF PREVENTABLE DEATHS (2017-2022). JACC. 2026 Apr, 87 (13_Supplement) A95–A96. https://doi.org/10.1016/j.jacc.2026.02.237

8) Choi, K, Kim, C, Spatz, E. et al. 26-A-11791-ACC SINGLE-PILL COMBINATIONS FOR HYPERTENSION MANAGEMENT: WIDELY RECOMMENDED, RARELY USED. JACC. 2026 Apr, 87 (13_Supplement) A301–A302. https://doi.org/10.1016/j.jacc.2026.02.746

9) Sivakumar, N., Danpanichkul, P., & Sripusanapan, A. (2026). 26-A-12343-ACC cardiovascular benefits of telmisartan in metabolic dysfunction associated steatotic liver disease. JACC, 87, A270. https://doi.org/10.1016/j.jacc.2026.02.670

10) Alrubaye, L, Alkarawi, H, Abdelwahed, A. et al. 26-A-17873-ACC BLOOD PRESSURE VARIABILITY AS A NOVEL PREDICTOR OF MORTALITY AND STROKE: UPDATED META-ANALYSIS. JACC. 2026 Apr, 87 (13_Supplement) A219. https://doi.org/10.1016/j.jacc.2026.02.541

11) Baseline Characteristics of Black and Hispanic Adults with Hypertension in Healthy Food Priority Areas: The THRIVE Food-is-Medicine Pilot Trial India Washington, et al, the THRIVE Food-is-Medicine Team medRxiv 2025.09.22.25336404; doi: https://doi.org/10.1101/2025.09.22.25336404

12) Laffin, L, Wang, Q, Sarraju, A. et al. Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial. JACC. null2026, 0 (0) . https://doi.org/10.1016/j.jacc.2026.03.034

13) Raja, F, Biradar, M, Patel, V. et al. 26-A-10499-ACC EFFECTIVENESS OF LOW-DOSE COMBINATION THERAPY VERSUS STANDARD CARE IN REDUCING SYMPTOMS AMONG HYPERTENSIVE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. JACC. 2026 Apr, 87 (13_Supplement) A266. https://doi.org/10.1016/j.jacc.2026.02.660

14) Ferro KM, et al. Nutrition Intervention of Groceries for Black Residents of Boston to Stop Hypertension (GoFresh) Among Adults With or Without Treated Hypertension Trial: Rationale, Design, and Evidence to Promote Implementation. Res Sq [Preprint]. 2025 Jul 7:rs.3.rs-6222158. doi: 10.21203/rs.3.rs-6222158/v1. Update in: Trials. 2025 Dec 3;26(1):560. doi: 10.1186/s13063-025-09273-z. PMID: 40671805; PMCID: PMC12265185.

15) Indian Society of Hypertension (InSH) Consensus Guideline for the Management of Hypertension, 2025doi: 10.61081/htnj/25v11i401

16) Gradman, A. H., Parisé, H., Lefebvre, P., Falvey, H., Lafeuille, M.-H., & Duh, M. S. (2013). Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: A matched cohort study. Hypertension, 61(2), 309–318. https://doi.org/10.1161/HYPERTENSIONAHA.112.201566

17) Neldam, S., Lang, M., & Jones, R. (2011). Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: Results of the TEAMSTA-5 study. Journal of Clinical Hypertension, 13(7), 459–466. https://doi.org/10.1111/j.1751-7176.2011.00468.x

18) Das AK, Tiwaskar M, Abdullakutty J, Pande A, Kumar V, Zalte N, Sugumaran A, Mohanasundaram S, Gogtay J. Effectiveness and Safety of the Telmisartan and Amlodipine Fixed-dose Combination in Managing Hypertension among Indian Patients (TACT India Study): Rationale and Study Design. J Assoc Physicians India. 2024 Nov;72(11):e16-e20. doi: 10.59556/japi.72.0743. PMID: 39563123.

19) START-RENAL Study: A prospective, open-label, randomized, multicenter, post-marketing study comparing the effectiveness and safety of telmisartan + amlodipine versus telmisartan + cilnidipine in subjects with hypertension and renal impairment over a 52-week study duration. Presented in: Tighter Control Matters Conclave. ACC 2026 updates: Translating evidence into practice [Video]. YouTube. April 4, 2026. https://www.youtube.com/live/X2X5YUt82lc

PYC - TEAM/0426/01